Results 161 to 170 of about 181,335 (186)

[Effects of Huanglian Jiedu Decoction on glucose transporter 4 in target tissues of type 2 diabetic rats].

Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2009
To investigate the molecular mechanism of Huanglian Jiedu Decoction (HLJDD), a traditional Chinese compound herbal medicine, in treating type 2 diabetes mellitus (T2DM) by observing its effects on glucose transporter 4 (GLUT4) protein expression and translocation in adipose and skeletal muscle tissues of rats with T2DM.T2DM was induced in rats by ...
Guang, Chen, Fu-er, Lu, Li-jun, Xu
openaire   +1 more source

Nitric Oxide/Glucose Transporter Type 4 Pathway Mediates Cardioprotection against Ischemia/Reperfusion Injury under Hyperglycemic and Diabetic Conditions in Rats

Journal of Vascular Research
<b><i>Introduction:</i></b> The comorbidities of ischemic heart disease (IHD) and diabetes mellitus (DM) compromise the protection of the diabetic heart from ischemia/reperfusion (I/R) injury. We hypothesized that manipulation of reperfusion injury salvage kinase (RISK) and survivor activating factor enhancement (SAFE) pathways ...
Aisha, Al-Kouh, Fawzi, Babiker
openaire   +2 more sources

Expression of miR-93 and Glucose Transporter Type 4 Mediated by Ginkgolide in Peripheral Blood with Polycystic Ovary Syndrome and Its Clinical Significance

Journal of Biobased Materials and Bioenergy
Decreased Glucose transporter 4 (GLUT4) expression leads to abnormal glucose regulation. miR-93 regulates GLUT4 expression and studies have shown that, ginkgolide mediates miR-93 and GLUT4 in polycystic ovary syndrome (PCOS). 50 patients with PCOS and 50 healthy women were recruited. RT-qPCR detected miR-93 and GLUT4 expression.
Jie Yuan, Yuqi Qiao, Yanru Lin
openaire   +1 more source

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials

EClinicalMedicine, 2021
Natalie Staplin, Alistair J Roddick, Jonathan Emberson   +2 more
exaly  

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor

Diabetes and Vascular Disease Research, 2015
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph   +2 more
exaly  

Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: A systematic review and meta-analysis of 48 randomized controlled trials

Pharmacological Research, 2020
Adriana Sanchez-Garcia, Mario Simental-Mendia, Juan Manuel Millán-Alanís   +2 more
exaly  

Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides

Proceedings of the National Academy of Sciences of the United States of America, 2016
Khyati Kapoor, Janet Finer-Moore, Holger Siebeneicher   +2 more
exaly  

Downregulation of Blood-Brain Barrier Glucose Transporter in Experimental Diabetes

Diabetes, 1990
William M Pardridge, D Triguero, Pardridge William M   +2 more
exaly  

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

European Journal of Heart Failure, 2019
John J V Mcmurray, Anna Maria Langkilde, Mirta Diez   +2 more
exaly  

In "Diabetic type 2 patients" ,is "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors" associated with " more effective control of serum glucose compered to "DPP-4 Inhibitors" ?

2023
Ramadan, Mohamed, Elshafie, Mohamed Ahmed, Morad, Mohamed   +2 more
openaire   +1 more source